Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the USA / NCT07846254
Recruiting Not applicable

The Effects of Daily Supplementation of a Soluble Fiber on the Fecal Microbiota in Volunteers.

NCT07846254 · tracked via the Priya Life Science USA tracker
Sponsor
Roquette Freres
Phase
Not applicable
Started
2026-08-31
Last updated
2026-09-29

Condition(s) studied

Healthy Volunteers

Investigational drug(s) / intervention(s)

NUTRIOSE®Active comparator

NUTRIOSE®: After randomization (V1 visit), the subjects will consume per os, from V1 to V2, 1 sachet per day, in the morning, of NUTRIOSE® during 4 weeks. They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot).

Active comparator: After randomization (V1 visit), the subjects will consume per os, from V1 to V2, 1 sachet per day, in the morning, of GLUCIDEX® IT19 during 4 weeks. They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot).

Study summary

The effects of daily supplementation with NUTRIOSE® on the fecal microbiota. The study aims to evaluate the ability of NUTRIOSE® to support a beneficial modulation of the intestinal microbiota in healthy volunteers, compared with a placebo.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Men and women aged ≥ 18 and ≤ 60 years; * Body mass index (BMI) ≥ 18 and ≤ 30 kg/m²; * With a usual normal intestinal transit (according to BSS). According to stool questionnaire completed between V0 and V1, mean of the 7 days of completion, maximum 3 stools / day and 3 stools/week minimum and with mean normal consistency * Good general and mental health according to the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination; * Agreement to maintain lifestyle habits during the study (same dietary and physical habits); * Able and willing to participate in the study by complying with the protocol procedures as evidenced by a dated and signed informed consent form (ICF); * Affiliated with a social security scheme; Exclusion Criteria: * Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic disorder; * Suffering from gastrointestinal disorders such as celiac disease, Crohn's disease, functional constipation, irritable bowel syndrome or another gastrointestinal found to be inconsistent with the study according to the investigator; * Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or biliary disorders ongoing, uncontrolled cardiac disease, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or another severe disorders found to be inconsistent with the conduct of the study by the investigator; * With a known food allergy or intolerance or hypersensitivity to any ingredient of the IP; * Pregnant or lactating women or intending to become pregnant within 6 months ahead; * Having undergone recent surgical procedure in the past 6 months or planned on the 2 months to come; * Under treatment which could significantly affect parameter(s) followed during the study according to the investigator or stopped less than 4 weeks before the V0 visit, i.e. medication with impact on intestinal transit such as anti-diarrheal, anti-spasmodic,antidepressants antibiotics, antacids, laxative, antifungal, NSAI, anti-vomiting, GLP-1 receptor agonists, corticoids, opioids, narcotic analgesic and biliary acids chelator, and chronic hormonal treatment started less than 3 months ago (i.e. new method of hormonal contraception, thyroidal trouble treatment); * Regular intake of dietary supplements or "health foods", or products known to impact intestinal microbiota, containing or rich in prebiotics, probiotics, symbiotic, fibre, fermented milk or yogurt, kefir, ultra-yeast, vitamins and minerals, or stopped less than 3 months before the inclusion visit. * With significant change in dietary or physical activity habits in the 3 months before randomization (no hyper or hypocaloric diet, no high-protein diet, no prolonged fasting for more than one week, no planned change in the level of sports activity in the next 3 months); * Taking part in another clinical study or being in the exclusion period of a previous clinical study; * Under legal protection (guardianship, wardship) or deprived of his rights following the administrative or judicial decision; * Presenting psychological or linguistic incapability to sign the ICF; * Impossible to contact in case of emergency.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Mérieux NutriSciences Addison Illinois Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07846254 on ClinicalTrials.gov ↗ ← All trials in the USA